Upcoming Events

There are currently no events scheduled.

Past Events

There are no past events to display.
2017 | 2016 | 2015 | 2014 | 2013
 

DateTitle 
Apr. 19, 2017Juno Therapeutics Appoints Rupert Vessey to Board of Directors
SEATTLE--(BUSINESS WIRE)--Apr. 19, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced it has appointed to its Board of Directors Dr. Rupert Vessey, President of Research and Early Development of Celgene Corporation. Dr. Vessey brings significant drug development capabilities to the Juno Board. Before joining Celgene in Januar... 
Printer Friendly Version
Apr. 17, 2017Juno Therapeutics Appoints Sunil Agarwal as President of Research and Development
Experienced executive addition with proven leadership and drug development expertise in emerging fields of medicine SEATTLE--(BUSINESS WIRE)--Apr. 17, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced it has appointed Sunil Agarwal, M.D., as President of Research and Development. With Dr. Agarwal’s appointment, Juno will bring R... 
Printer Friendly Version
Mar. 01, 2017Juno Therapeutics Reports Fourth Quarter and 2016 Financial Results
– Nine product candidates in clinical trials against eight different targets – – Pivotal trial for JCAR017 in r/r DLBCL expected to start in 2017 – – Phase I JCAR017 demonstrates 80% overall response and 60% complete response in r/r DLBCL – – Discontinuing development of JCAR015 in r/r adult ALL to focus on defined cell product in this setting – – 2016 year end cash position of $922.3 million – – 2017... 
Printer Friendly Version
Feb. 28, 2017Juno Therapeutics to Present at March 2017 Investor Conferences
SEATTLE--(BUSINESS WIRE)--Feb. 28, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentations at two investor conferences in March. The presentations will feature a business overview and update. Hans Bishop, Juno’s President and Chief Executive Officer, will present at the Cowen and Company 37th Annual Health Care Conference at 10:40 a.m. ET on Tuesday, March 7, 2017. ... 
Printer Friendly Version
Feb. 22, 2017Juno Therapeutics to Report Full Year and Fourth Quarter 2016 Financial Results on Wednesday, March 1
SEATTLE--(BUSINESS WIRE)--Feb. 22, 2017-- Juno Therapeutics, Inc. (NASDAQ:JUNO) will announce financial results for the fourth quarter and year ended December 31, 2016, on Wednesday, March 1, 2017, after the close of U.S.-based financial markets. Following the announcement, Juno management will host a conference call and live webcast to provide a business update and discuss financial results beginning at 2:00 p.m. Pacific Time (PT) / 5:00 p.m. Eastern ... 
Printer Friendly Version
Jan. 27, 2017Juno Therapeutics Appoints Corsee D. Sanders as Executive Vice President and Head of Development Operations
Experienced executive brings demonstrated operational excellence to Juno, will lead newly formed group focused on development operations SEATTLE--(BUSINESS WIRE)--Jan. 27, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced the appointment of Corsee D. Sanders, Ph.D., as Executive Vice President and Head of Development Operations, effect... 
Printer Friendly Version
Jan. 03, 2017Juno Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
SEATTLE--(BUSINESS WIRE)--Jan. 3, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentation at the 35th Annual J.P. Morgan Healthcare Conference at 4:30 p.m. PT on Tuesday, January 10, 2017. The presentation will feature a business overview and update by Hans Bishop, Juno’s President and Chief Executive Officer. The webcast will be accessible on the Investor Relations page of Juno's website at www.... 
Printer Friendly Version